Workflow
Anixa Biosciences(ANIX) - 2025 Q1 - Quarterly Report
ANIXAnixa Biosciences(ANIX)2025-03-11 20:20

Revenue Performance - Revenue for the three months ended January 31, 2025, was 0,consistentwiththesameperiodin2024[81].−Thecompanydoesnotexpecttobegingeneratingrevenuefromitscurrenttherapyorvaccineprogramsinthenearterm[82].Expenses−Researchanddevelopmentexpensesincreasedbyapproximately0, consistent with the same period in 2024[81]. - The company does not expect to begin generating revenue from its current therapy or vaccine programs in the near term[82]. Expenses - Research and development expenses increased by approximately 203,000 to approximately 1,552,000forthethreemonthsendedJanuary31,2025,comparedtoapproximately1,552,000 for the three months ended January 31, 2025, compared to approximately 1,349,000 in the same period in 2024[84]. - General and administrative expenses decreased by approximately 426,000toapproximately426,000 to approximately 1,834,000 for the three months ended January 31, 2025, from approximately 2,260,000inthesameperiodin2024[86].−Interestincomedecreasedbyapproximately2,260,000 in the same period in 2024[86]. - Interest income decreased by approximately 146,000 to approximately 173,000forthethreemonthsendedJanuary31,2025,fromapproximately173,000 for the three months ended January 31, 2025, from approximately 319,000 in the same period in 2024[87]. Assets and Cash Flow - Total current assets decreased by approximately 2,676,000toapproximately2,676,000 to approximately 18,686,000 as of January 31, 2025, compared to approximately 21,362,000atOctober31,2024[90].−Cashusedinoperatingactivitieswasapproximately21,362,000 at October 31, 2024[90]. - Cash used in operating activities was approximately 2,904,000 for the three months ended January 31, 2025[91]. - Cash provided by investing activities was approximately 2,703,000,resultingfromthematuritiesofshort−terminvestmentsofapproximately2,703,000, resulting from the maturities of short-term investments of approximately 15,700,000[91]. - The company has approximately 97millionofcommonstockavailableforsaleunderitsat−the−marketequityprogramasofJanuary31,2025[90].NetLoss−Thenetlossattributabletononcontrollinginterestdecreasedbyapproximately97 million of common stock available for sale under its at-the-market equity program as of January 31, 2025[90]. Net Loss - The net loss attributable to noncontrolling interest decreased by approximately 6,000 to approximately $29,000 for the three months ended January 31, 2025[88].